Persistent Tertiary Hyperparathyroidism: Parathyroidectomy or One More Medical Trial
Three years after a living-donor transplant, a patient's calcium has stayed high on maximal cinacalcet — the question is whether that ceiling has genuinely been reached, or whether one more step in imaging and medical therapy is still owed before surgery.
Angela R., a 51-year-old librarian, received a living-donor kidney from her brother three years ago after a decade of polycystic kidney disease, and has spent most of the time since rebuilding a garden she'd let go fallow during her years on dialysis — though lately the bone pain in her knees has made the kneeling and crouching harder than she expects it should be at 51. Her graft has functioned well throughout, which is part of why the persistent abnormality in her calcium has taken this long to become the focus it now is.
Her corrected calcium has held at 11.4 mg/dL across three separate checks over four months — a persistence, not a fluctuation, and unchanged despite cinacalcet that had already reached its maximum tolerated dose, over a six-month titration, two months before the first of those three checks was drawn. This is tertiary hyperparathyroidism: parathyroid tissue that grew autonomous during years of pre-transplant secondary disease and never fully involuted once the graft restored normal kidney function, now secreting PTH independent of the calcium level it should be responding to. Before her transplant, her PTH had run well above a thousand for the better part of two years on dialysis, high enough for long enough that the group isn't especially surprised some of that parathyroid tissue never got the signal to stand down once her brother's kidney started working for her. A new DEXA shows osteopenia that wasn't present before her transplant, and a renal ultrasound obtained for an unrelated reason picked up early nephrocalcinosis in a graft that has otherwise functioned without complaint. The evidence on parathyroidectomy in this setting cuts in two directions at once, and which way it points depends on when the surgery happens. Callender and colleagues found that parathyroidectomy performed before transplant reduces subsequent graft failure. Surgery performed after a graft is already working shows the opposite short-term signal: Evenepoel and colleagues' case-controlled series found a significant rise in serum creatinine following post-transplant parathyroidectomy, and a 2024 meta-analysis of twelve studies found measurably lower GFR and higher creatinine a full year after surgery. Graft survival in the Evenepoel series was nonetheless no different from controls, and the creatinine rise partly reversed over several years. So the honest reading for Angela is that surgery is the reliable way to fix her calcium and is not the way to protect her graft — her window for the graft-protective version of this operation closed three years ago.
At the transplant-nephrology mineral-bone review
Three flat calcium checks over four months at her maximum tolerated cinacalcet dose is medical failure by any reasonable definition. I want to be careful about how I argue this, though, because the obvious argument is the wrong one: Evenepoel's series and the more recent meta-analysis both show graft function declining after post-transplant parathyroidectomy, not improving. So I'm not offering surgery as graft protection. I'm offering it because she has sustained hypercalcemia at 11.4, new osteopenia, and early nephrocalcinosis, and the only drug we have for it has stopped moving the number.
You're right that three flat labs across four months at max dose is a real ceiling, not a monitoring gap — I'm not disputing that the medical trial has run its course. What gives me pause is doing this without imaging — and I'd add that you've just made my case for me on the graft. If the expected creatinine trajectory after this operation is upward, then every avoidable complication matters more, not less. Hungry bone syndrome after parathyroidectomy can produce acute, sometimes severe hypocalcemia on top of that, and I'd rather not put both stresses on a graft that's functioned this well for three years without first confirming what we're actually operating on.
That's the piece I'd add before either of you commits fully. We haven't localized the overactive tissue — a sestamibi scan tells the surgical team what to expect and gives us one more confirmatory look before an irreversible step, without costing meaningful time given how long this has already been building. If it's concordant with the clinical picture, which I expect it will be, that removes the imaging question as a reason to delay further.
Agreed: obtain a sestamibi scan, proceed to subtotal parathyroidectomy if the imaging is concordant with the clinical picture, and continue her current cinacalcet dose as a bridge in the interim.
Not agreed: whether earlier surgery, without waiting for imaging, would already have been reasonable given three already-flat labs. The surgeon held that confirmatory imaging remains the standard regardless of how convinced the nephrology team already is on the underlying question. Also left unresolved, and flagged explicitly rather than smoothed over: how much of an expected post-operative fall in graft function the group is willing to accept as the price of ending her hypercalcemia — a trade nobody in the room disputed exists, and nobody was willing to put a number on.